Interferon Enhances the Expression of Epstein—Barr Virus Early Antigen in Daudi Cells Free

Abstract

SUMMARY

Treatment of the Burkitt lymphoma-derived cell line Daudi with highly purified human interferon-α (IFN-α) increased up to 100-fold the number of cells expressing Epstein—Barr virus (EBV)-determined early antigen (EA) without inducing the synthesis of virus capsid antigen (VCA), a late virus function. The increase in the number of EA-positive cells was proportional to interferon concentration up to 10 international units (IU)/ml. Treatment of Daudi cells with the same number of units of either partially purified (sp. act. 10 IU/mg protein) or electrophoretically pure (sp. act. 2 × 10 IU/mg protein) IFN-α both gave a similar increase in EA expression, strongly suggesting that the effects observed were indeed due to interferon. Furthermore, treatment of relatively interferon-insensitive Raji cells with IFN-α (1 to 10 IU/ml) had no significant effect on either spontaneous or 5-iodo-2′-deoxyuridine (IdUrd)-induced expression of EA or VCA. Human IFN-β also enhanced the expression of EBV EA in Daudi cells. In contrast, when the latent EBV present in Daudi cells was activated to enter into a replicative cycle, either by induction with IdUrd or by superinfection with the non-transforming PHR1 strain of EBV, then treatment with human IFN-α caused a marked inhibition of EA expression. Our results suggest that interferon can exert a differential action on virus replication depending upon the state of the virus genome within the cell.

Keyword(s): EBV , interferon , latency and virus induction
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-60-1-31
1982-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/60/1/JV0600010031.html?itemId=/content/journal/jgv/10.1099/0022-1317-60-1-31&mimeType=html&fmt=ahah

References

  1. Adams A. 1979; The state of the virus genome in transformed cells and its relationship to host cell DNA. In The Epstein–Barr Virus pp 155–183 Edited by Epstein M. A., Achong B. G. New York: Springer-Verlag;
    [Google Scholar]
  2. Adams A., Strander H., Cantell K. 1975; Sensitivity of the Epstein–Barr virus-transformed human lymphoid cell lines to interferon. Journal of General Virology 28:207–217
    [Google Scholar]
  3. Billiau A., Edy V. G., Sobis H., De Somer P. 1974; Influence of interferon on virus particle synthesis in oncornavirus-carrier lines. II. Evidence for a direct effect on particle release. Internationa! Journal of Cancer 14:335–340
    [Google Scholar]
  4. Blazar B., Patarroyo M., Klein E., Klein G. 1980; Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein–Barr virus cycle by superinfection or sodium butyrate. Journal of Experimental Medicine 151:614–627
    [Google Scholar]
  5. De The G. 1980; Role of Epstein–Barr virus in human disease: infectious mononucleosis, Burkitt’s lymphoma and nasopharyngeal carcinoma. In Viral Oncology pp 769–797 Edited by Klein G. New York: Raven Press;
    [Google Scholar]
  6. Epstein L. B. 1976; The ability of macrophages to augment in vitro mitogen and antigen stimulated production of interferon and other mediators of cellular immunity by lymphocytes. In Immunology of Macrophage pp 201–234 Edited by Nelson D. S. New York: Academic Press;
    [Google Scholar]
  7. Ernberg I., Klein G. 1979; Epstein–Barr virus induced antigens. In The Epstein–Barr Virus pp 40–60 Edited by Epstein M. A., Achong B. G. New York: Springer-Verlag;
    [Google Scholar]
  8. Fellous M., Kamoun M., Gresser I., Bono R. 1979; Enhanced expression of HLA antigens and pi microglobulin on interferon treated human lymphoid cells. European Journal of Immunology 9:446–449
    [Google Scholar]
  9. Fellous M., Bono R., Hyalfil F., Gresser I. 1981; Interferon enhances the amount of membrane bound pi microglobulin and its release from human Burkitt cells. European Journal of Immunology 11:524–526
    [Google Scholar]
  10. Friedman R. M. 1979; Interferons: interactions with cell surfaces. In Interferon vol I: pp 53–74 Edited by Gresser I. London: Academic Press;
    [Google Scholar]
  11. Friedman R. M., Ramseur J. M. 1974; Inhibition of murine leukemia virus production in chronically infected AKR cells. A novel effect of interferon. Proceedings of the National Academy of Sciences of the United States of America 71:3542–3544
    [Google Scholar]
  12. Gerber P. 1972; Activation of Epstein–Barr virus by 5-bromodeoxyuridine in ‘virus-free’ human cells. Proceedings of the National Academy of Sciences of the United States of America 69:83–85
    [Google Scholar]
  13. Green J. A., Cooperband S. R., Kibrick S. 1969; Immune specific induction of interferon production in cultures of human blood lymphocytes. Science 164:1415–1417
    [Google Scholar]
  14. Greenberg J. S., Philips M., Stephenson J. R., Aaronson S. A. 1975; Induction of mouse type-C RNA virus by lipopolysaccharide. Journal of Immunology 115:317–320
    [Google Scholar]
  15. Gresser I., Tovey M. G. 1978; Antitumor effects of interferon. Biochimica et Biophysica Acta 516:231–247
    [Google Scholar]
  16. Gresser I., Tovey M. G., Bandu M.-T., Maury C., Brouty-Boye D. 1976a; Role of interferon in the pathogenesis of virus disease in mice as demonstrated by use of anti-interferon serum. I. Rapid evolution of EMC virus infection. Journal of Experimental Medicine 144:1305–1315
    [Google Scholar]
  17. Gresser I., Tovey M. G., Maury C., Bandu M. T. 1976b; Role of interferon in the pathogenesis of virus disease in mice as demonstrated by use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease and influenza viruses. Journal of Experimental Medicine 144:1316–1323
    [Google Scholar]
  18. Hampar B. 1979; Activation of the viral genome in vitro. In The Epstein–Barr Virus pp 284–295 Edited by Epstein M. A., Achong B. G. New York: Springer-Verlag;
    [Google Scholar]
  19. Hampar B., Derge J. G., Martos L. M., Walker J. L. 1972; Synthesis of Epstein–Barr virus after activation of the viral genome in a ‘virus-negative’ human lymphoblastoid cell (Raji) made resistant to 5 -bromodeoxyuridine. Proceedings of the National Academy of Sciences of the United States of America 69:72–82
    [Google Scholar]
  20. Havell E. A., Vilcek J. 1972; Production of high-titered interferon in cultures of human diploid cells. Antimicrobial Agents and Chemotherapy 2:476–478
    [Google Scholar]
  21. Henle W., Diehl V., Kohn G., Zur Hausen H., Henle G. 1967; Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157:1064–1065
    [Google Scholar]
  22. Hirsch M. S., Ellis D. A., Black P. H., Monaco A. P., Wood M. L. 1973; Leukemia virus activation during homograft rejection. Science 180:500–502
    [Google Scholar]
  23. Lindahl P., Leary P., Gresser I. 1973; Enhancement by interferon of the expression of surface antigens on murine leukemia L1210 cells. Proceedings of the National Academy of Sciences of the United States of America 70:2785–2788
    [Google Scholar]
  24. Lindahl P., Leary P., Gresser I. 1974; Enhancement of the expression of histocompatibility antigens of mouse lymphoid cells by interferon in vitro. European Journal of Immunology 4:779–784
    [Google Scholar]
  25. Lucka J., Kallin B., Klein G. 1979; Induction of the Epstein–Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228–231
    [Google Scholar]
  26. Mogensen K. E., Cantell K. 1977; Production and preparation of human leukocyte interferon. Pharmacology and Therapeutics Cl:369–381
    [Google Scholar]
  27. Mogensen K. E., Cantell K. 1979; Non-specific adsorption of interferon to immobilized serum immunoglobulin. Journal of General Virology 45:171–175
    [Google Scholar]
  28. Mogensen K. E., Bandu M.-T., Vignaux F., Aguet M., Gresser I. 1981; Binding of 125I-labelled human a-interferon to human lymphoid cells. International Journal of Cancer 28:575–582
    [Google Scholar]
  29. Moroni C., Schumann G., Robert-Guroff M., Suter E. R., Martin D. 1975; Induction of endogenous murine C-type virus in spleen cell cultures treated with mitogens and 5-bromo-2′ deoxyuridine. Proceedings of the National Academy of Sciences of the United States of America 72:535–538
    [Google Scholar]
  30. Mozes L. W., Defendi V. 1979; The differential effect of interferon on T antigen production in simian virus 40 -infected or transformed cells. Virology 93:558–568
    [Google Scholar]
  31. Olding L. B., Jensen F. C., Oldstone M. B. A. 1975; Pathogenesis of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. Journal of Experimental Medicine 141:561–572
    [Google Scholar]
  32. Stewart W. E. II 1979; The Interferon System. New York: Springer-Verlag;
    [Google Scholar]
  33. Tovey M. G. 1980; Viral latency and its importance in human disease. Pathologie Biologie 26:631–634
    [Google Scholar]
  34. Tovey M. G., Begon-Lours J., Gresser I., Morris A. G. 1977; Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells. Nature, London 276:270–272
    [Google Scholar]
  35. Tovey M. G., Lenoir G., Begon-Lours J., Tapiero H., Rochette-Egly C. 1979; The effect of mitogens on the expression of Epstein–Barr virus antigens in human lymphoid cell lines. Journal of Immunology 123:138–142
    [Google Scholar]
  36. Wu B. C., Dowling J. N., Armstrong J. A., Ho M. 1975; Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science 190:56–58
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-60-1-31
Loading
/content/journal/jgv/10.1099/0022-1317-60-1-31
Loading

Data & Media loading...

Most cited Most Cited RSS feed